0000000000955771

AUTHOR

Giuseppe De Cataldis

showing 1 related works from this author

Safety and efficacy of irinotecan plus high-dose leucovorin and intravenous bolus 5-fluorouracil for metastatic colorectal cancer: pooled analysis of…

2005

Abstract Background A biweekly regimen of irinotecan 200 mg/m2 on day 1 and levo-leucovorin (LV) 250 mg/m2 plus 5-fluorouracil (5-FU) 850 mg/m2 via intravenous bolus on day 2 was assessed in 2 consecutive randomized trials in metastatic colorectal cancer (CRC). Patients and Methods Individual data of 254 patients were merged, and baseline features potentially affecting overall response rate (ORR), progression-free survival (PFS),overall survival (OS), and occurrence of severe toxicity were analyzed by univariate and multivariate analyses. Results In the pooled series, ORR was 33% (95% confidence interval [CI], 27%-39%). Liver-only disease (47% vs. 25%; P = 0.0012) and absence of previous we…

OncologyAdultMalemedicine.medical_specialtySettore MED/06 - Oncologia MedicaLeucovorinNeutropeniaIrinotecanDrug Administration ScheduleInjectionsWeight lossInternal medicineAntineoplastic Combined Chemotherapy ProtocolsWeight Loss80 and overMedicineHumansNeoplasm MetastasisAgedAged 80 and overPerformance statusbusiness.industryHazard ratioGastroenterologyAge FactorsMiddle Agedmedicine.diseaseOxaliplatinIrinotecanRegimenTreatment OutcomeOncologyFluorouracilInjections IntravenousCamptothecinFemaleFluorouracilAge Factors; Drug Administration Schedule; Injections Intravenous; Humans; Aged; Leucovorin; Camptothecin; Aged 80 and over; Fluorouracil; Weight Loss; Adult; Treatment Outcome; Neoplasm Metastasis; Antineoplastic Combined Chemotherapy Protocols; Middle Aged; Male; Colorectal Neoplasms; Femalemedicine.symptomIntravenousbusinessColorectal Neoplasmsmedicine.drugClinical colorectal cancer
researchProduct